What is KPV?

Three amino acids cut from a hormone you already make

KPV is shorthand for lysine-proline-valine, the three amino acids that make up the molecule. It is not a synthetic invention. It is the C-terminal fragment of alpha-melanocyte-stimulating hormone, or alpha-MSH, a naturally occurring 13-amino-acid peptide your pituitary gland and skin cells produce. KPV corresponds to positions 11 through 13 of that hormone, the tail end of the molecule.

Alpha-MSH itself does a lot: it drives skin pigmentation, appetite signaling, and immune regulation, all through melanocortin receptors spread across the body. KPV is small enough that researchers can isolate just its anti-inflammatory piece. It does not bind those melanocortin receptors and does not raise intracellular cAMP, so it skips the pigment and hormonal effects entirely while keeping the anti-inflammatory activity researchers care about.

How KPV is thought to work

The mechanism researchers have documented is NF-kB inhibition. NF-kB is a protein complex that switches on inflammatory genes inside cells. In intestinal epithelial cells and immune cells, KPV blocks the degradation of IkB-alpha, a protein that normally holds NF-kB in check. Keep IkB-alpha intact and NF-kB cannot activate, so the inflammatory cascade that follows never gets going.

That is a receptor-independent mechanism, which is part of why KPV shows up in research on two very different tissue types, gut lining and skin, that both rely heavily on NF-kB signaling when they get inflamed.

What the animal research actually shows

The strongest data set uses DSS-induced and TNBS-induced colitis in mice, two standard lab models for inflammatory bowel disease. Across multiple studies, KPV lowered disease activity scores, reduced histological damage to the intestinal lining, cut myeloperoxidase activity, a marker of neutrophils flooding into inflamed tissue, and improved the gut barrier's ability to keep itself sealed.

The detail that gets researchers' attention: KPV worked even when given orally. Most peptides do not survive stomach acid and digestive enzymes intact, which is why GLP-1 drugs like semaglutide either get injected or, for the oral versions, packaged with an absorption enhancer just to get a fraction of the dose through. At three residues, KPV is small enough to make it through gastrointestinal transit in a workable amount, at least in mice. A second, smaller body of research looks at KPV for inflamed and wounded skin, again mostly in cell culture and animal models rather than people.

The FDA's July 2026 review, and what staff actually found

KPV is one of seven peptides FDA staff evaluated ahead of the Pharmacy Compounding Advisory Committee's July 23-24, 2026 hearing, a review that also covers BPC-157 and TB-500. The question in front of the committee is narrow: should KPV go on the 503A Bulk Drug Substances List, the list that lets licensed compounding pharmacies fill a physician-written prescription under formal FDA quality standards. FDA staff posted their briefing conclusion on June 30, 2026, and it is a no.

The gap is not about the animal data, which staff did not dispute. It is about people. FDA staff said they could not identify any human exposure data on drug products containing KPV, administered by any route, in the medical literature. No completed human trial. No documented case series. Nothing showing how KPV behaves in a person's body at any dose, for any length of time. Combined with the same characterization concerns that showed up across all seven substances in this round, inconsistent naming between the free base and acetate salt forms, that left staff without a basis to recommend inclusion.

Where KPV sits among the other peptides under review

KPV shares its hearing slot with three other peptides on July 23: BPC-157, TB-500, and MOTS-c. A second day, July 24, covers emideltide, Semax, and epitalon. FDA staff reached the same conclusion for all seven: not enough characterization data, not enough effectiveness data, not enough safety data to support adding any of them to the list. Among the four peptides reviewed on July 23, KPV and MOTS-c share the same specific gap, zero human clinical evidence of any kind, while BPC-157 and TB-500 at least had a handful of small, flawed studies FDA staff could point to and reject on the merits.

The public comment docket for this hearing, FDA-2025-N-6895, closes today, July 22, the day before the committee convenes. Comments filed before the close become part of the record the committee reviews ahead of its vote.

What this means if you are considering KPV today

Nothing about your ability to buy KPV changes this week no matter which way the vote goes. It was never FDA-approved, and a 503A Bulks List decision only touches whether a licensed compounding pharmacy can fill a prescription for it under formal FDA authorization. The online research-chemical market that sells most KPV today operates outside that system entirely and keeps operating regardless of the outcome.

The more useful takeaway is about the evidence itself. The mouse colitis data is real, published in peer-reviewed journals, and mechanistically coherent. It is not the same thing as knowing what KPV does in a human body, and right now nobody, including the FDA, has that answer. For how KPV fits into the broader peptide landscape and what else people commonly pair with a GLP-1, see our peptide stacks guide, and for the full picture of this week's hearing, our preview of the July 23-24 PCAC meeting.